Active Research Protocols

  1. 01-C-0070 – Evaluation of the Natural History of Patients with Tumors of the Central Nervous System
  2. 02-C-0140 – A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative
  3. 02-C-0193 – A Phase II Study of Pegylated Interferon Alfa-2b (Peg-Intron (TM)) in Children with Diffuse Pontine Gliomas
  4. 05-C-0136 – A Phase I Trial of Enzastaurin (LY317615) in Patients with Recurrent Gliomas
  5. 05-C-0137 – A Phase II Trial of Tamoxifen and Bortezomib in Patients with Recurrent High-Grade Gliomas
  6. 06-C-0063 – A Phase I/II Trial of ZD6474 for Patients with Recurrent High-Grade and Progressive Low-Grade Gliomas
  7. 06-C-0064 – A Phase II Trial of Bevacizumab for Patients with Recurrent High-Grade Gliomas
  8. 06-C-0112 – A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination with Temodar and Radiation Therapy in Patients with High Grade Gliomas: Multi-Institutional Trial
  9. 06-C-0250 – A Phase II Trial of Bevacizumab and Irinotecan for Patients with Recurrent High-Grade Gliomas Immediately Following Tumor Progression after Treatment w/Bevacizumab Alone: A Companion Trial to NCI Study 06-C-0064 (Bevacizumab Alone for Recurrent Gliomas)
  10. 06-N-0085 – Two-Compartment Model of Diffusion Tensor Magnetic Resonance Imaging (DT-MRI) for the Diagnosis of Glioma Tumor Recurrence versus Radiation Necrosis
  11. 07-C-0053 – A Phase I Trial of Enzastaurin (LY317615) in Combination with Carboplatin in Adults with Recurrent Gliomas
  12. 08-C-0015 – A Phase II Trial of Enzastaurin (LY317615) in Combination with Bevacizumab in Adults with Recurrent Malignant Gliomas
  13. 08-C-0101 – A Phase 2 Trial of Tandutinib in Combination with Bevacizumab for Patients with Recurrent High-Grade Gliomas
  14. 08-C-0168 – A Phase II Trial of Sunitinib in the Treatment of Recurrent Malignant Gliomas
  15. 09-C-0080 – A Phase 2, Open-label, Proof-of-Concept Study to Assess the Ability to Detect Tumours and Angiogenesis via the Expression of Alpha v Beta 3 Integrin Receptors by (18F)AH-111585 PET Imaging
  16. 09-C-0222 – A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination with Carboplatin versus Carboplatin Alone Followed by Vandetanib Alone in Adults with Recurrent High-Grade Gliomas
  17. 09-C-0243 – A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-Ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors
  18. 09-N-0117 – An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients with Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-Grade Glioma
  19. 10-C-0219 – A Phase I Trial of Lenalidomide and Radiotherapy in Children with Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas
  20. 11-C-0036 – A Pilot Study of Inpatient Hospice with Procurement of Brain Tumor Tissue on Expiration for Research Purposes
  21. 11-C-0122 – Phase I Trial of AZD8055, An Oral MTOR Kinase Inhibitor, for Adults with Recurrent Gliomas
  22. 11-C-0191 – Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
  23. 11-C-0192 – A Phase I Trial of Peptide-Based Glioma Vaccine IMA950 in Patients with Glioblastoma (GBM)
  24. 11-C-0266 – A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients with Malignant Gliomas Expressing EGFRvIII
  25. 11-N-0204 – Prospective, Randomized Controlled Trial of Surgical Resection Prior to Bevacizumab Therapy for Recurrent Glioblastoma Multiforme
  26. 12-C-0004 – A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma
  27. 12-C-0005 – Phase I Trial of AZD7451, A Topomysin-Receptor Kinase (TRK) Inhibitor, For Adults with Recurrent Glioblastoma Multiforme (GBM)
  28. 12-C-0058 – A Phase II Study of Everolimus (RAD001) for Children with Neurofibromatosis Type-1 and Chemotherapy-Refractory Radiographic Progressive Low-Grade Gliomas
  29. 12-C-0136 – A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
  30. 97-C-0093 – A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients with Primary and Metastatic Brain Tumors
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014